The use of antibodies against the IL-2 receptor in transplantation

Current Opinion in Immunology

Volumn 10, Issue 5, 1998, Pages 507-512

  Waldmann, Thomas A ^a   O'Shea, John ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

CLINICAL TRIAL; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY TRANSPLANTATION; SHORT SURVEY;

EID: 0031786786     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(98)80215-X     Document Type: Article

References (66)

1. Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J Immunol. 126:1981;1398-1403.
2. Tsudo M, Kozak RW, Goldman CK, Waldmann TA. Demonstration of a new (non-Tac) peptide that binds interleukin-2: a potential participant in a multichain interleukin-2 receptor complex. Proc Natl Acad Sci USA. 83:1986;9694-9698.
3. Sharon M, Klausner RD, Cullen BR, Chizzonite R, Leonard WJ. Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science. 234:1986;859-863.
4. Takeshita T, Asao H, Ohtani K, Ishii N, Kumaki S, Tanaka N, Munakata H, Nakamura M, Sugamura K. Cloning of the γ chain of the human IL-2 receptor. Science. 257:1992;379-382.
5. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell. 73:1993;5-8.
6. Waldmann TA. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today. 14:1993;264-270.
7. Waldmann TA. The interleukin-2 receptor. J Biol Chem. 266:1991;2681-2684.
8. Depper JM, Leonard WJ, Robb RJ, Waldmann TA, Greene WC. Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J Immunol. 131:1983;690-696.
9. Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Ythier A, Strom TB. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med. 162:1985;358-362.
10. Kirkman RL, Barrett LV, Koltun WA, Diamantstein T. Prolongation of murine cardiac allograft survival by the anti- interleukin-2 receptor monoclonal antibody AMT-13. Transplant Proc. 19:1987;618-619.
11. Kupiec-Weglinski JW, Padberg W, Uhteg LC, Ma L, Lord RH, Araneda D, Strom TB, Diamantstein T, Tilney NL. Selective immunosuppression with anti-interleukin 2 receptor-targeted therapy: helper and suppressor cell activity in rat recipients of cardiac allografts. Eur J Immunol. 17:1987;313-319.
12. Wood MJA, Sloan DJ, Dallman MJ, Charlton HM. Specific tolerance to neural allografts induced with an antibody to the interleukin 2 receptor. J Exp Med. 177:1993;597-603.
13. Reed MH, Shapiro ME, Strom TB, Milford EL, Carpenter CB, Weinberg DS, Reimann KA, Letvin NL, Waldmann TA, Kirkman RL. Prolongation of primate renal allograft survival by anti-Tac, an anti- human IL-2 receptor monoclonal antibody. Transplantation. 47:1989;55-59.
14. Cooper MM, Robbins RC, Waldmann TA, Gansow OA, Clark RE. Use of anti-Tac antibody in primate cardiac xenograft transplantation. Surgical Forum. 39:1988;353-355.
15. Waldmann TA, Goldman CK, Bongiovanni KF, Sharrow SO, Davey MP, Cease KB, Greenberg SJ, Longo DL. Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood. 72:1988;1805-1816.
16. Soulillou JP, Cantarovich D, Le Mauff B, Giral M, Robillard N, Hourmant M, Hirn M, Jacques Y. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med. 322:1990;1175-1182.
17. Kirkman RL, Shapiro ME, Carpenter CB, McKay DB, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, Strom TB. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation. 51:1991;107-113.
18. Cantarovich D, Le Mauff B, Hourmant M, Dantal J, Baatard R, Denis M, Jacques Y, Karam G, Paineau J, Soulillou JP. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. I. Results after combined pancreas and kidney transplantation. Transplantation. 57:1994;198-203.
19. Neuhaus B, Keck H, Bechstein WO, Blumhardt G, Langrehr JM, Wiens M, Lemmens HP, Lohmann R, Schlag H, Thalmann U, Weidermann H. Quadruple induction immunosuppression after liver transplantation with IL-2 receptor antibody (BT 563) is equally effective and better tolerated than ATG induction therapy. Transplant Proc. 25:1993;587-589.
20. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA. 86:1989;10029-10033.
21. Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 50:1990;1495-1502.
22. Brown PS Jr, Parenteau GL, Dirbas FM, Garsia RJ, Goldman CK, Bukowski MA, Junghans RP, Queen C, Hakimi J, Benjamin WR, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA. 88:1991;2663-2667.
23. Hakimi J, Chizzonite R, Luke DR, Familletti PC, Bailon P, Kondas JA, Pilson RS, Lin P, Weber DV, Spencer C, et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol. 147:1991;1352-1359.
24. Queen C, Schneider WP, Waldmann T. Humanized antibodies to the IL-2 receptor. Clark M. Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man. 1993;159-170 Academic Titles, Nottingham.
25. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. of outstanding interest N Engl J Med. 338:1998;161-165 This is the first description of the phase III, randomized, placebo-controlled trial involving standard cyclosporin-based immunosuppressive therapy wherein the anti-IL2-receptor antibody daclizumab was shown to significantly reduce the rate of renal allograft rejection. On the basis of this study the Food and Drug Administration gave marketing clearance for daclizumab to prevent acute kidney transplant rejection.
26. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M, et al. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science. 264:1994;965-968.
27. Bamford RN, Grant AJ, Burton JD, Peters C, Kurys G, Goldman CK, Brennan J, Roessler E, Waldmann TA. The interleukin (IL) 2 receptor β chain is shared by IL-2 and a cytokine, provisionally designated IL-T that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA. 91:1994;4940-4944.
28. Kondo M, Takeshita T, Ishii N, Nakamura M, Watanabe S, Arai K-I, Sugamura K. Sharing of the interleukin-2 (IL-2) receptor γ chain between receptors for IL-2 and IL-4. Science. 262:1993;1874-1877.
29. Noguchi M, Nakamura Y, Russell SM, Ziegler SF, Tsang M, Cao X, Leonard WJ. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science. 262:1993;1877-1880.
30. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA. 87:1990;6934-6938.
31. Johnston JA, Kawamura M, Kirken RA, Chen Y-Q, Blake TB, Shibuya K, Ortaldo JR, McVicar DW, O'Shea JJ. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature. 370:1994;151-153.
32. Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, Liu ET, Ihle JN. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature. 370:1994;153-157.
33. Johnston JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, Shibuya K, Ortaldo JR, Gupta S, Chen YQ, Giri JD, O'Shea JJ. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci USA. 92:1995;8705-8709.
34. Lin J-X, Migone T-S, Tsang M, Friedmann M, Weatherbee JA, Zhou L, Yamauchi A, Bloom ET, Mietz J, John S, Leonard WJ. The role of shared receptor motifs and common Stat proteins in the generation of cytokine plelotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity. 2:1995;331-339.
35. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology function, and clinical application. Ann Intern Med. 113:1990;619-627.
36. Vincenti F, Lantz M, Birnbaum J, Garovoy M, Mould D, Hakimi J, Nieforth K, Light S. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. of special interest Transplantation. 63:1997;33-38 This is a description of the phase I/II trial involving humanized anti-IL-2-receptor (daclizumab) in the prevention of acute graft rejection in renal transplant recipients.
37. edn 53 The Physicians Desk Reference. 1999;Medical Economics Production Company, Montvale, New Jersey. in press.
38. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. of special interest Lancet. 350:1997;1193-1198 This is a description of the reduction in acute graft rejection episodes in renal transplant recipients receiving the chimeric monoclonal antibody against the IL-2 receptor α chain, basiliximab.
39. Guex-Crosier Y, Raber J, Chan C-C, Kriete MS, Benichou J, Pilson RS, Kerwin JA, Waldmann TA, Hakimi J, Roberge FG. Humanized antibodies against the α-chain of the IL-2 receptor and againsts the β-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol. 158:1997;452-458.
40. MacLean JA, Su Z, Guo Y, Sy MS, Colvin RB, Wong JT. Anti-CD3:anti-IL-2 receptor bispecific monoclonal antibody. Targeting of activated T cells in vitro. J Immunol. 150:1993;1619-1628.
41. Strom TB, Kelley VR, Murphy JR, Nichols J, Woodworth TG. Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules. Annu Rev Med. 44:1993;343-353.
42. Kreitman RJ, Chaudhary VK, Waldmann TA, Hanchard B, Cranston B, FitzGerald DJP, Pastan I. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia. 7:1993;553-562.
43. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, Brechbiel MW, Jaffe ES, Fleisher TA, Goldman CK, et al. Radioimmunotherapy of interleukin-2R α-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood. 86:1995;4063-4075.
44. Schwarz UP, Plascjak P, Beitzel MP, Gansow OA, Eckelman WC, Waldmann TA. Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets. Nucl Med Biol. 25:1998;89-93.
45. Parenteau GL, Dirbas FM, Garmestani K, Brechbiel MW, Bukowski MA, Goldman CK, Clark R, Gansow OA, Waldmann TA. Prolongation of graft survival in primate allograft transplantation byyttrium-90-labeled anti-Tac in conjunction with granulocyte colony- stimulating factor. Transplantation. 54:1992;963-968.
46. Tsudo M, Goldman CK, Bongiovanni KF, Chan WC, Winton EF, Yagita M, Grimm EA, Waldmann TA. The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proc Natl Acad Sci USA. 84:1987;5394-5398.
47. Giri JG, Kumaki S, Ahdieh M, Friend DJ, Loomis A, Shanebeck K, DuBose R, Cosman D, Park LS, Anderson DM. Identification and cloning of a novel IL-15 binding protein that is structurally related to the α chain of the IL-2 receptor. EMBO J. 14:1995;3654-3663.
48. Gourlay WA, Chambers WH, Monaco AP, Maki T. Importance of natural killer cells in the rejection of hamster skin xenografts. Transplantation. 65:1998;727-734.
49. Pavlakis M, Strehlau J, Lipman M, Shapiro M, Maslinski W, Strom TB. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation. 62:1996;543-545.
50. Manfro RC, Roy-Chaudhury P, Zheng XX, Steiger J, Nickerson PW, Li Y, Maslinski W, Strom TB. Interleukin-15 gene transcripts are present in rejecting islet allografts. Transplant Proc. 29:1997;1077-1078.
51. Tinubu SA, Hakimi J, Kondas JA, Bailon P, Familletti PC, Spence C, Crittenden MD, Parenteau GL, Dirbas FM, Tsudo M, et al. Humanized antibody directed to the IL-2 receptor β-chain prolongs primate cardiac allograft survival. J Immunol. 153:1994;4330-4338.
52. Pilson RS, Levin W, Desai B, Reik LM, Lin P, Korkmaz-Duffy E, Campbell E, Tso JY, Kerwin JA, Hakimi J. Bispecific humanized anti-IL-2 receptor αβ antibodies inhibitory for both IL-2- and IL-15-mediated proliferation. J Immunol. 159:1997;1543-1556.
53. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 270:1995;797-800.
54. Macchi P, Villa A, Gillani S, Sacco MG, Frattini A, Porta F, Ugazio AG, Johnston JA, Candotti F, O'Shea JJ, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 377:1995;65-68.
55. Candotti F, Oakes SA, Johnston JA, Giliani S, Schumacher RF, Mella P, Fiorini M, Ugazio AG, Badolato R, Notarangelo LD, et al. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood. 90:1997;3996-4003.
56. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science. 270:1995;794-797.
57. Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, Doherty PC, Grosveld GC, Ihle JN. Defective lymphoid development in mice lacking Jak3. Science. 270:1995;800-802.
58. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KC, Yin L, Pennica D, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 93:1998;373-383.
59. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 93:1998;385-395.
60. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 16:1998;293-322.
61. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 93:1998;841-850.
62. Aman MJ, Leonard WJ. Cytokine signaling: cytokine-inducible signaling inhibitors. Curr Biol. 7:1997;R784-R788.
63. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ. A family of cytokine-inducible inhibitors of signaling. Nature. 387:1997;917-921.
64. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature. 387:1997;924-929.
65. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 387:1997;921-924.
66. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. Specific inhibition of Stat3 signal transduction by PIAS3. Science. 278:1997;1803-1805.